
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7137064/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Journal of Urology, 2022, 207, 16-24.	0.4	31
2	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clinical Cancer Research, 2022, 28, 738-747.	7.0	11
3	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
4	Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK) Journal of Clinical Oncology, 2022, 40, TPS398-TPS398.	1.6	3
5	Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis) Journal of Clinical Oncology, 2022, 40, 316-316.	1.6	1
6	Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC) Journal of Clinical Oncology, 2022, 40, 304-304.	1.6	0
7	Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer, 2022, 20, 210-218.	1.9	4
8	Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211086.	3.2	15
9	Emerging Biomarker-Guided Therapies in Prostate Cancer. Current Oncology, 2022, 29, 5054-5076.	2.2	10
10	Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma. Canadian Urological Association Journal, 2021, 15, 281-286.	0.6	7
11	Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). Kidney Cancer, 2021, 5, 21-29.	0.4	3
12	Can incomplete metastasectomy impact renal cell carcinoma outcomes? A propensity score matching analysis from a prospective multicenter collaboration. Société Internationale D'urologie Journal, 2021, 2, 82-95.	0.4	0
13	Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. JAMA Oncology, 2021, 7, 773.	7.1	21
14	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical Genitourinary Cancer, 2021, 19, 521-530.	1.9	8
15	Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. Canadian Urological Association Journal, 2021, 15, 353-358.	0.6	2
16	The perceptions and beliefs of cannabis use among Canadian genitourinary cancer patients. Canadian Urological Association Journal, 2021, 16, .	0.6	1
17	PD40-07 CLINICAL OUTCOMES AND ADVERSE EVENTS AFTER FIRST-LINE TREATMENT IN METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. Journal of Urology, 2021, 206, .	0.4	1
18	Cabozantinib realâ€world effectiveness in the firstâ€through fourthâ€line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Medicine, 2021, 10, 1212-1221.	2.8	22

#	Article	IF	CITATIONS
19	The emerging treatment landscape of advanced urothelial carcinoma. Current Opinion in Supportive and Palliative Care, 2021, Publish Ahead of Print, 247-252.	1.3	1
20	Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report. Current Oncology, 2021, 28, 226-232.	2.2	2
21	State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. European Urology Focus, 2020, 6, 37-40.	3.1	6
22	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. European Urology Oncology, 2020, 3, 372-381.	5.4	59
23	From Famine to Feast: Treating Urinary Malignancies in the Immunotherapy Era. European Urology Focus, 2020, 6, 1-2.	3.1	2
24	Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European Urology Oncology, 2020, 3, 695-699.	5.4	30
25	Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From The Canadian Kidney Cancer Information System (CKCis). International Journal of Radiation Oncology Biology Physics, 2020, 108, e887.	0.8	0
26	211: Outcomes of Radiotherapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCIS). Radiotherapy and Oncology, 2020, 150, S89-S90.	0.6	0
27	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Kidney Cancer, 2020, 4, 119-119.	0.4	Ο
28	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. European Journal of Cancer, 2020, 135, 203-210.	2.8	50
29	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. JCO Global Oncology, 2020, 6, 293-306.	1.8	4
30	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Canadian Urological Association Journal, 2020, 15, 84-97.	0.6	11
31	Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) Journal of Clinical Oncology, 2020, 38, 639-639.	1.6	3
32	Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK) Journal of Clinical Oncology, 2020, 38, TPS761-TPS761.	1.6	12
33	Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis) Journal of Clinical Oncology, 2020, 38, 682-682.	1.6	2
34	Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade. , 2020, , .		0
35	Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis) Journal of Clinical Oncology, 2020, 38, 633-633.	1.6	0
36	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) Journal of Clinical Oncology, 2020, 38, 642-642.	1.6	9

#	Article	IF	CITATIONS
37	Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2020, 38, 620-620.	1.6	1
38	Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). Annals of Oncology, 2019, 30, v396.	1.2	4
39	CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology, 2019, 30, v885.	1.2	12
40	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Canadian Urological Association Journal, 2019, 13, 343-54.	0.6	10
41	Response of Primary Renal Cell Carcinoma to Systemic Therapy. European Urology, 2019, 76, 852-860.	1.9	9
42	Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2019, 14, 122-129.	0.6	3
43	A A Canadian consensus forum on the management of patients with advanced prostate cancer. Canadian Urological Association Journal, 2019, 14, E137-E149.	0.6	15
44	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications, 2019, 10, 4346.	12.8	139
45	Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. Canadian Urological Association Journal, 2019, 14, E154-E158.	0.6	15
46	Capturing recurrence in urothelial carcinoma: "more than meets the eye― Translational Andrology and Urology, 2019, 8, S524-S527.	1.4	0
47	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.	0.6	3
48	Systemic treatments for metastatic urothelial carcinoma. Expert Opinion on Pharmacotherapy, 2019, 20, 201-208.	1.8	12
49	Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. European Urology, 2019, 75, 100-110.	1.9	178
50	Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis) Journal of Clinical Oncology, 2019, 37, 4516-4516.	1.6	6
51	Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2019, 37, 566-566.	1.6	9
52	Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis) Journal of Clinical Oncology, 2019, 37, 568-568.	1.6	3
53	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. British Journal of Cancer, 2018, 118, 1238-1242.	6.4	33
54	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunology Research, 2018, 6, 402-408.	3.4	56

ALY-KHAN A LALANI

#	Article	IF	CITATIONS
55	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Canadian Urological Association Journal, 2018, 13, 166-174.	0.6	10
56	Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC). Annals of Oncology, 2018, 29, viii311.	1.2	9
57	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer, 2018, 119, 707-712.	6.4	28
58	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). British Journal of Cancer, 2018, 118, 1434-1441.	6.4	34
59	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. , 2018, 6, 5.		200
60	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2018, 6, 758-765.	3.4	89
61	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. Kidney Cancer, 2018, 2, 31-36.	0.4	10
62	JAVELIN: avelumab another spear to fight urothelial carcinoma. Lancet Oncology, The, 2018, 19, 5-7.	10.7	2
63	Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2018, 36, 607-607.	1.6	12
64	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma Journal of Clinical Oncology, 2018, 36, 626-626.	1.6	1
65	CD73 expression in primary and metastatic renal cell carcinoma (RCC) Journal of Clinical Oncology, 2018, 36, 643-643.	1.6	1
66	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy Journal of Clinical Oncology, 2018, 36, 667-667.	1.6	0
67	Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis Journal of Clinical Oncology, 2018, 36, 629-629.	1.6	0
68	Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non–Lymph Node Distant Metastasis. Clinical Genitourinary Cancer, 2017, 15, e1089-e1094.	1.9	3
69	Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nature Communications, 2017, 8, 199.	12.8	49
70	Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 724-732.	1.9	34
71	Immunotherapy in the Elderly. European Urology Focus, 2017, 3, 403-412.	3.1	16
72	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Canadian Urological Association Journal, 2017, 11, 112.	0.6	32

#	Article	IF	CITATIONS
73	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66.		37
74	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC). Annals of Oncology, 2017, 28, v314-v315.	1.2	0
75	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression Journal of Clinical Oncology, 2017, 35, 4573-4573.	1.6	1
76	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis) Journal of Clinical Oncology, 2017, 35, 468-468.	1.6	4
77	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget, 2017, 8, 103428-103436.	1.8	19
78	Proton pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2017, 35, 493-493.	1.6	0
79	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis) Journal of Clinical Oncology, 2017, 35, e16078-e16078.	1.6	0
80	Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT) Journal of Clinical Oncology, 2017, 35, e16065-e16065.	1.6	0
81	Outcomes of women with small, early-stage breast cancer in Manitoba from 2006-2011 Journal of Clinical Oncology, 2017, 35, e12000-e12000.	1.6	0
82	Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience. Annals of Oncology, 2016, 27, vi285.	1.2	1
83	Abstract P3-07-13: Outcomes of women with small, early-stage breast cancer in Manitoba from 1995-2011. , 2015, , .		0
84	Manifestations of Von Hippel Lindau syndrome: a retrospective national review. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 291-296.	0.5	10